

# Appendix 3Y

## Change of Director's Interest Notice

<b>Name of entity</b>	<b>Incannex Healthcare Limited</b>
<b>ABN</b>	<b>93 096 635 246</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Sudhanshu AGARWAL
<b>Date of last notice</b>	07 Sept 2021

### Part 1 - Change of director's relevant interests in securities

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest</b>	Dr Agarwal is a shareholder, CEO and director of Cannvalate Pty Ltd ("Cannvalate"). 'Indirect' positions disclosed in this Appendix 3Y are held by Cannvalate - Dr Agarwal does <b>not</b> have sole discretion over the acquisition or disposal of these positions.
<b>Date of change</b>	06 October 2021
<b>No. and class of securities held prior to change</b>	<b>Direct</b> 54,303,593 fully paid ordinary shares ("IHL") 180,000,000 \$0.20 unlisted options expiry 30-Sep-21 <b>Indirect</b> 32,000,000 fully paid ordinary shares ("IHL")
<b>Number and class of securities acquired</b>	20,999,500
<b>Number and class of securities disposed</b>	Nil
<b>Value/Consideration</b>	\$ 4,199,900
<b>No. of securities held after change</b>	<b>Direct</b> 75,303,093 fully paid ordinary shares ("IHL") <b>Indirect</b> 32,000,000 fully paid ordinary shares ("IHL")
<b>Nature of change</b>	Conversion of \$0.20 unlisted options expiry 30-Sep-21

### Part 2 – Change of director's interests in contracts – no change

### Part 3 – Closed period

<b>Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/a
<b>If prior written clearance was provided, on what date was this provided?</b>	N/a